Financial Architects Inc Sells 4,400 Shares of Valeant Pharmaceuticals (NYSE:VRX)

Financial Architects Inc lowered its stake in Valeant Pharmaceuticals (NYSE:VRX) (TSE:VRX) by 29.2% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,650 shares of the specialty pharmaceutical company’s stock after selling 4,400 shares during the quarter. Financial Architects Inc’s holdings in Valeant Pharmaceuticals were worth $247,000 as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in VRX. Envestnet Asset Management Inc. increased its position in Valeant Pharmaceuticals by 189.4% during the first quarter. Envestnet Asset Management Inc. now owns 5,991 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 3,921 shares during the last quarter. Bedel Financial Consulting Inc. acquired a new position in Valeant Pharmaceuticals during the second quarter worth approximately $116,000. Assetmark Inc. increased its position in Valeant Pharmaceuticals by 409.4% during the first quarter. Assetmark Inc. now owns 11,498 shares of the specialty pharmaceutical company’s stock worth $183,000 after buying an additional 9,241 shares during the last quarter. Meag Munich Ergo Kapitalanlagegesellschaft MBH acquired a new position in Valeant Pharmaceuticals during the second quarter worth approximately $236,000. Finally, First Allied Advisory Services Inc. increased its position in Valeant Pharmaceuticals by 33.6% during the first quarter. First Allied Advisory Services Inc. now owns 15,101 shares of the specialty pharmaceutical company’s stock worth $242,000 after buying an additional 3,800 shares during the last quarter. 46.95% of the stock is currently owned by institutional investors and hedge funds.

A number of equities analysts have weighed in on VRX shares. Barclays raised Valeant Pharmaceuticals from an “equal weight” rating to an “overweight” rating and boosted their price target for the stock from $20.00 to $34.00 in a research report on Wednesday, June 6th. TD Securities downgraded Valeant Pharmaceuticals from a “buy” rating to a “hold” rating and set a $24.00 price target on the stock. in a research report on Friday, June 22nd. Cantor Fitzgerald set a $25.00 price target on Valeant Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday, May 14th. Mizuho raised Valeant Pharmaceuticals from a “neutral” rating to a “buy” rating in a research report on Tuesday, May 15th. Finally, Royal Bank of Canada boosted their price target on Valeant Pharmaceuticals from $18.00 to $19.00 and gave the stock a “sector perform” rating in a research report on Wednesday, May 9th. Four equities research analysts have rated the stock with a sell rating, nine have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $20.51.

Shares of NYSE:VRX traded down $0.83 during trading on Friday, reaching $23.40. 6,571,593 shares of the stock were exchanged, compared to its average volume of 6,356,695. Valeant Pharmaceuticals has a 12 month low of $10.94 and a 12 month high of $27.79. The stock has a market cap of $8.16 billion, a PE ratio of 6.11, a P/E/G ratio of 0.35 and a beta of -0.38. The company has a quick ratio of 0.92, a current ratio of 1.18 and a debt-to-equity ratio of 5.59.

Valeant Pharmaceuticals Company Profile

Valeant Pharmaceuticals International, Inc operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S.

Further Reading: How to Use a Moving Average for Trading 

Institutional Ownership by Quarter for Valeant Pharmaceuticals (NYSE:VRX)

Receive News & Ratings for Valeant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply